A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

被引：1
|
作者：
Lee, Hans C. [1 ]
Shah, Jatin J. [2 ]
Feng, Lei [3 ]
Morphey, Ashley [1 ]
Johnson, Ralph J. [1 ]
Wesson, Emily T. [1 ]
Wang, Michael L. [1 ]
Alexanian, Raymond [1 ]
Thomas, Sheeba K. [1 ]
Orlowski, Robert Z. [1 ,4 ]
Weber, Donna M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, 1515 Holcombe Blvd,Unit 429, Houston, TX 77030 USA
[2] Karyopharm Therapeut, Newton, MA USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2019年 / 94卷 / 12期
关键词：
DARATUMUMAB; POMALIDOMIDE;
D O I：
10.1002/ajh.25633
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E319 / E322
页数：4
相关论文
共 50 条
  • [1] Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma
    Shah, Jatin J.
    Orlowski, Robert Z.
    Alexanian, Raymond
    Wang, Michael
    Thomas, Sheeba
    Qazilbash, Muzaffar H.
    Parmar, Simrit
    Shah, Nina
    Bashir, Qaiser
    Popat, Uday
    Weber, Donna
    BLOOD, 2010, 116 (21) : 811 - 812
  • [2] Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma
    Shah, Jatin J.
    Orlowski, Robert Z.
    Thomas, Sheeba K.
    Alexanian, Raymond
    Wang, Michael
    Qazilbash, Muzaffar H.
    Popat, Uday R.
    Parmar, Simrit
    Shah, Nina
    Bashir, Qaiser
    Champlin, Richard E.
    Weber, Donna M.
    BLOOD, 2012, 120 (21)
  • [3] Ixazomib in Combination With Thalidomide and Dexamethasone as Treatment for Patients With Relapsed/Refractory Multiple Myeloma: An Ongoing Phase II Trial
    Ludwig, Heinz
    Lechner, Daniel
    Gunsilius, Eberhard
    Fridrik, Michael
    Petzer, Andreas
    Kuehr, Thomas
    Knop, Stefan
    Schreder, Martin
    Weisel, Katja
    Rauch, Elisabeth
    Poenisch, Wolfram
    Greil, Richard
    Zojer, Niklas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E75 - E75
  • [4] Phase I Trial of Perifosine, Lenalidomide, and Dexamethasone in Relapsed or Refractory Myeloma
    Jakubowiak, A. J.
    Hideshima, T.
    Sportelli, P.
    Gardner, L.
    Giusti, K.
    Richardson, P. G.
    Zimmerman, T.
    Alsina, M.
    Kaufman, J.
    Brozo, C.
    Kendall, T.
    McAllister, A.
    Harvey, C.
    Anderson, K. C.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S56 - S57
  • [5] Phase II study of thalidomide with dexamethasone for relapsed/refractory multiple myeloma
    Kinoshita, T
    Ohno, T
    Yuge, M
    Hiraga, J
    Matsushita, T
    Ando, S
    Naoe, T
    ANNALS OF ONCOLOGY, 2005, 16 : 206 - 206
  • [6] Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study
    Siegel, D. S.
    Weber, D. M.
    Mitsiades, C. S.
    Dimopoulos, M. A.
    Harousseau, J. L.
    Rizvi, S.
    Howe, J.
    Reiser, D.
    Anderson, K. C.
    Richardson, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Siegel, David
    Weber, Donna
    Mitsiades, Constantine S.
    Rizvi, Syed
    Garcia-Vargas, Jose
    Howe, Jason
    Reiser, David
    Anderson, Kenneth C.
    Richardson, Paul
    BLOOD, 2008, 112 (11) : 1270 - 1270
  • [8] Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    Paulus, Aneel
    Alegria, Victoria R.
    Laplant, Betsy
    Moustafa, Muhamad Alhaj
    Chapin, Dustin
    Jackson, Keisha
    Jani, Prachi
    Ahmed, Salman
    Edwards, Brett
    Manna, Alak
    Roy, Vivek
    Sher, Taimur
    Chanan-Khan, Asher A.
    BLOOD, 2019, 134
  • [9] Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results
    Ailawadhi, Sikander
    Parrondo, Ricardo D.
    Moustafa, Muhamad Alhaj
    LaPlant, Betsy R.
    Alegria, Victoria
    Chapin, Dustin
    Roy, Vivek
    Sher, Taimur
    Paulus, Aneel
    Chanan-Khan, Asher A.
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (04) : 695 - 703
  • [10] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
    Yasuo Mori
    Ilseung Choi
    Goichi Yoshimoto
    Tsuyoshi Muta
    Satoshi Yamasaki
    Kazuki Tanimoto
    Tomohiko Kamimura
    Hiromi Iwasaki
    Ryosuke Ogawa
    Koichi Akashi
    Toshihiro Miyamoto
    International Journal of Hematology, 2020, 111 : 673 - 680
12345